No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Established in 1992 and headquartered in Xinyang, China, Henan Lingrui Pharmaceutical Co., Ltd. specializes in the production and distribution of pharmaceutical products throughout the Chinese market. The company offers a broad catalog of approximately 100 different medications, provided in ten distinct dosage formats such as adhesive plasters, tablets, capsules, granules, and tinctures. Prominent items in their product line include Tongluoqutong plasters, Peiyuantongnao capsules, Danlutongdu tablets, stomachache free tablets, and Shenqi Hypoglycemic capsules.
www.lingrui.comNo one on the platform currently holds 600285.SS.
No tracked institution reports a position in 600285.SS as of their last filing.
No one on the platform has traded 600285.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 22.5% | 31.0% | 23.8% | — | — | — |
| Rev. Growth % | 10.1% | 10.6% | ||||
| Profit Margin % | 19.7% | 17.3% | 16.2% | |||
| Free Cash Flow Margin % | 12.9% | 22.8% | 14.8% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $4.1B | +4.8% | $1.50 | $1.49–$1.52 | — | 1 |
| 2027 | $4.5B | +8.5% | $1.63 | $1.61–$1.65 | — | 1 |
| 2028 | $4.9B | +8.4% | $1.79 | $1.75–$1.84 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 600285.SSHenan Lingrui Pharmaceutical Co., Ltd. | $19.16 | -0.57% | $10.9B | — |
| 002550.SZChangzhou Qianhong Biopharma CO.,LTD | $6.27 | -0.63% | $7.7B | — |
| 002626.SZXiamen Kingdomway Group Company | $16.23 | +0.56% | $9.9B | — |
| 600211.SSTibet Rhodiola Pharmaceutical Holding Co. Class A | $35.62 | -1.36% | $11.5B | — |
| 600216.SSZhejiang Medicine Co., Ltd. |
| $12.39 |
| -0.80% |
| $11.9B |
| — |
| 600267.SSZhejiang Hisun Pharmaceutical Co., Ltd. | $11.38 | +0.71% | $13.4B | — |
| 600420.SSShanghai Shyndec Pharmaceutical Co., Ltd. | $8.18 | -0.85% | $11.0B | — |
Source: Financial Modeling Prep · peers by sector/industry